Does generic lamotrigine lead to larger variations in plasma concentrations?;Giver generika af lamotrigin anledning til større svingninger i plasmakoncentrationen?

Ugeskrift for Laeger

Volumn 169, Issue 21, 2007, Pages 2013-2015

  Buck, Thomas Croft ^a,b   Schmedes, Anne ^a   Brandslund, Ivan ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b Region Syddanmark   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG; LAMOTRIGINE; TRIAZINE DERIVATIVE;

ARTICLE; BLOOD; COMPARATIVE STUDY; EPILEPSY; HUMAN;

ANTICONVULSANTS; DRUGS, GENERIC; EPILEPSY; HUMANS; TRIAZINES;

EID: 34249663876     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. www.laegemiddelstyrelsen.dk/ maj 2006.
2. www.irf.dk/dk/publikationer/rationel_farmakoterapi/maanedsblad/2006/ godkendelse_af_generika.htm/ september 2006.
3. www.epilepsiforeningen.dk/artikler/horingref0602.pdf september 2006.
4. Johannessen SI, Battino D, Berry DJ et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003;25:347-63.
5. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000;38:191-204.
6. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000;55:697-705.
7. Bartoli A, Guerrini R, Belmonte A et al. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997;19:252-60.
8. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 1996;37:534-8.
9. Meyer MC, Straughn AB, Mhatre RM et al. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res 1998;15:1787-91.
10. Silpakit O, Amornpichetkoon M, Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother 1997;31:548-52.
11. Sharma C, Dubey R, Kumar H. Food reduces the bioavailability of lamotrigine. Indian J Med Res 2005;121:659-64.
12. Sabers A, Buchholt JM, Uldall P et al. Lamotrigene plasma levels reduced by oral contraceptives. Epilepsy Res 2001;47:151-4.
13. Sabers A, Ohman I, Christensen J et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-1.
14. Sidhu J, Job S, Singh S et al. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2006;61:191-9.
15. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005;46:1414-7.
16. Zaccara G, Messori A, Cincotta M et al. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006;114:157-68.